Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3828753 | Revista Clínica Española | 2008 | 4 Pages |
Abstract
Factors related to the patient, the stent, the coronary lesion and the technique are involved in the pathogenesis of ST. The main risk factor ST is the premature discontinuation of antiplatelet therapy. Currently, patients must receive aspirin and a thienopyridine for at least one month after the implantation of a bare-metal stent and 12 months after the implantation of a drug-eluting stent, then maintaining one antiplatelet agent indefinitely
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
D. Martà Sánchez, N. Dedieu, L. Salido Tahoces, J.L. Mestre Barceló, J. Pey Illera,